ChiCTR2300070280 版本V1.0 版本创建时间2023/04/07 15:30:39 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300070280 

最近更新日期:

Date of Last Refreshed on:

2023-04-07 15:30:22 

注册时间:

Date of Registration:

2023-04-07 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

结合中医证候的血液透析患者心血管事件死亡率风险临床预测模型建立与外部验证

Public title:

Establishment and external validation of a clinical prediction model for the risk of cardiovascular event mortality in hemodialysis patients combined with TCM syndromes

注册题目简写:

English Acronym:

研究课题的正式科学名称:

结合中医证候的血液透析患者心血管事件死亡率风险临床预测模型建立与外部验证

Scientific title:

Establishment and external validation of a clinical prediction model for the risk of cardiovascular event mortality in hemodialysis patients combined with TCM syndromes

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨敏 

研究负责人:

杨敏 

Applicant:

Yangmin 

Study leader:

Yangmin 

申请注册联系人电话:

Applicant telephone:

18902331002

研究负责人电话:

Study leader's telephone:

18902331002

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sherry0728@163.com

研究负责人电子邮件:

Study leader's E-mail:

sherry0728@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

广东省中医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区大德路111号透析科

研究负责人通讯地址:

广东省广州市越秀区大德路111号透析科

Applicant address:

Department of Dialysis, No. 111 Dade Road, Yuexiu District, Guangzhou, Guangdong Province

Study leader's address:

Department of Dialysis, No. 111 Dade Road, Yuexiu District, Guangzhou, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

510120

研究负责人邮政编码:

Study leader's postcode:

510120

申请人所在单位:

广州中医药大学第二附属医学院广东省中医院

Applicant's institution:

Guangdong Provincial Hospital of Traditional Chinese Medicine, Second Affiliated Medical College of Guangzhou University of Chinese Medicine

研究负责人所在单位:

广州中医药大学第二附属医学院广东省中医院

Affiliation of the Leader:

Guangdong Provincial Hospital of Traditional Chinese Medicine, Second Affiliated Medical College of Guangzhou University of Chinese Medicine

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

BE2020-278-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020-12-21 00:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Lixiaoyan

伦理委员会联系地址:

广东省广州市越秀区大德路111号伦理委员会

Contact Address of the ethic committee:

No. 111 Dade Road, Yuexiu District, Guangzhou, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

020-81887233-35943

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州中医药大学第二附属医学院广东省中医院

Primary sponsor:

Guangdong Provincial Hospital of Traditional Chinese Medicine, Second Affiliated Medical College of Guangzhou University of Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号透析科

Primary sponsor's address:

Department of Dialysis, No. 111 Dade Road, Yuexiu District, Guangzhou, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广州中医药大学第二附属医学院广东省中医院

具体地址:

广东省广州市越秀区大德路111号

Institution
hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine, Second Affiliated Medical College of Guangzhou University of Chinese Medicine

Address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong

经费或物资来源:

广东省中医药管理局科研基金

Source(s) of funding:

Scientific Research Fund of Guangdong Provincial Administration of Traditional Chinese Medicine

Target disease:

Hemodialysis

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

本研究建立2个预测模型,比较全因死亡率和心血管事件死亡率的影响因素,并评估HD患者的长期生存率。  

Objectives of Study:

In this study, two predictive models were established to compare the factors of all-cause mortality and cardiovascular event mortality, and to evaluate the long-term survival of HD patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

符合血液透析标准;经医院伦理委员会批准者。

Inclusion criteria

Meet the hemodialysis criteria; Approved by the ethics committee of the hospital.

排除标准:

血液透析时间小于3个月;有肾移植或腹膜透析史。

Exclusion criteria:

The exclusion criteria included hemodialysis duration of fewer than 3 months, the outcome of kidney transplantation, and history of peritoneal dialysis.

研究实施时间:

Study execute time:

From 2020-07-01 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-07-01 00:00:00 To 2022-10-31 00:00:00  

干预措施:

Interventions:

组别:

连续入组

样本量:

551

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

广州中医药大学第二附属医学院广东省中医院 

单位级别:

三级甲等 

Institution
hospital:

Guangdong Provincial Hospital of Traditional Chinese Medicine, The Second Affiliated Medical College of Guangzhou University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

死亡结局

指标类型:

主要指标

Outcome:

mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

3年、5年、8年生存率

指标类型:

次要指标

Outcome:

3-year, 5-year, and 8-year survival rates

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

死亡结局原因分类

指标类型:

次要指标

Outcome:

Classification of causes of death outcomes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 22 years
最大 Max age 88 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台 http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical Trial Management Public Platform http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-04-07 15:30:22